Cutler Group LP Cel Sci Corp Put Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 Apr 14, 2022	SELL	$3.93 - $7.7 $786 - $1,540	-200 Reduced 66.67%	100 $0
Q4 2021 Jan 18, 2022	SELL	$7.1 - $12.82 $24,850 - $44,870	-3,500 Reduced 92.11%	300 $5,000
Q3 2021 Oct 26, 2021	SELL	$7.64 - $12.49 $619,604 - $1.01 Million	-81,100 Reduced 95.52%	3,800 $4,000
Q2 2021 Jul 19, 2021	BUY	$8.68 - $27.49 $719,572 - $2.28 Million	82,900 Added 4145.0%	84,900 $649,000
Q1 2021 Apr 26, 2021	SELL	$12.0 - $27.64 $206,400 - $475,408	-17,200 Reduced 89.58%	2,000 $11,000
Q4 2020 Jan 21, 2021	BUY	$11.05 - $16.62 $89,505 - $134,622	8,100 Added 72.97%	19,200 $14,000
Q3 2020 Oct 27, 2020	BUY	$11.69 - $14.54 $118,069 - $146,854	10,100 Added 1010.0%	11,100 $14,000
Q2 2020 Jul 22, 2020	SELL	$9.75 - $17.6 $40,950 - $73,920	-4,200 Reduced 80.77%	1,000 $9,000
Q1 2020 May 07, 2020	BUY	$7.54 - $17.05 $20,358 - $46,035	2,700 Added 108.0%	5,200 $17,000
Q4 2019 Feb 06, 2020	BUY	$6.71 - $9.55 $16,775 - $23,875	2,500 New	2,500 $2,000

6.16M

16.6K

148K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $46.8M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.